16081-45-1

Basic information

• Product Name: 5-Amino-1,4-benzodioxane
• Synonyms: 2,3-ETHYLENEDIOXYANILINE;5-AMINO-1,4-BENZODIOXANE;5-AMINO-1,4-BENZODIOXANE HYDROCHLORIDE;2,3-Dihydro-1,4-benzodioxin-5-amine;2,3-Dihydro-1,4-benzodioxin-5-amine hydrochloride;2,3-Dihydro-benzo[1,4]dioxin-5-ylamine;2,3-dihydrobenzo[b][1,4]dioxin-5-amine;1,4-Benzodioxan-5-amine, 95%
• CAS NO: 16081-45-1
• Molecular Formula: C₈H₉NO₂
• Molecular Weight: 151.16
• Product Categories: Amines;Benzomorpholines & Benzothiomorpholines;Anilines, Amides & Amines;Miscellaneous Compounds;Benzomorpholines & Benzothiomorpholines
• Mol File: 16081-45-1.mol

Chemical Properties

• Boiling Point: 276.282 °C at 760 mmHg
• Flash Point: 131.123 °C
• Appearance: Yellow to amber/Spherical Beads
• Density: 1.253 g/cm³
• Vapor Pressure: 0.005mmHg at 25°C
• Refractive Index: 1.6
• PKA: 4.06±0.20(Predicted)
• CAS DataBase Reference: 5-Amino-1,4-benzodioxane(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-1,4-benzodioxane(16081-45-1)
• EPA Substance Registry System: 5-Amino-1,4-benzodioxane(16081-45-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• Hazardous Substances Data: 16081-45-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-1,4-benzodioxane is used as a reactant for the preparation of aminoquinoline and pyrazolopyrimidine hybrids. These compounds have demonstrated potent antimalarial properties, making them valuable in the development of new treatments for malaria. The incorporation of 5-Amino-1,4-benzodioxane into these hybrid molecules contributes to their enhanced efficacy against the Plasmodium parasite, which is responsible for causing malaria.

InChI:InChI=1/C8H9NO2/c9-6-2-1-3-7-8(6)11-5-4-10-7/h1-3H,4-5,9H2

Upstream product

• 57356-28-2 5-nitro-2,3-dihydro-1,4-benzodioxin 
• 1116136-19-6 t-butyl (2,3-dihydrobenzo[b][1,4]dioxin-5-yl)carbamate 
• 6665-98-1 3-nitrobenzene-1,2-diol 
• 120-80-9 benzene-1,2-diol 
• 1155139-88-0 5-isocyanato-2,3-dihydrobenzo[b][1,4]dioxine 
• 4442-53-9 2,3-dihydro-1,4-benzodioxine-5-carboxylic acid 
• 7440-44-0 pyrographite 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 

Downstream Products

• 98224-03-4 eltoprazine 
• 153607-45-5 S 15931 
• 153607-44-4 S 14489 
• 184951-65-3 4-Benzyl-1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-3,5-dimethyl-piperazine-2,6-dione 

Relevant articles and documents

CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Disclosed are a condensed ring derivative, and a preparation method, an intermediate, a pharmaceutical composition and a use thereof. The condensed ring derivative of the present invention has a significant inhibitive effect on URAT1, which can effectively alleviate or treat hyperuricemia and other related diseases.

MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS

The present invention relates to compounds compound according to Formula (III); and pharmaceutically acceptable salts, hydrates and solvates thereof. These compounds have D2receptor antagonist/(partial) agonist effects and H3antagonistic effects, pharmaceutical compositions thereof, and methods of using them for application in the prophylaxis or treatment of CNS disorders.

2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS

The invention relates to a novel class of 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as a FAK and/or Pyk2 inhibitor, to a process for their preparation, and to a composition thereof, as well as to use of the compounds for the inhibiting FAK and/or Pyk2 and method for the treatment of a FAK and/ or Pyk2 mediated disorder or disease.

FUNCTIONALLY SELECTIVE LIGANDS OF DOPAMINE D2 RECEPTORS

The present invention relates to novel functionally selective ligands of dopamine D2 receptors, including agonists, antagonists, and inverse agonists. The invention further relates to the use of these compounds for treating central nervous system disorders related to D2 receptors.

Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2

Due to the emerging role of protein kinase CK2 as a molecule that participates not only in the development of some cancers but also in viral infections and inflammatory failures, small organic inhibitors of CK2, besides application in scientific research, may have therapeutic significance. In this paper, we present a new class of CK2 inhibitors-3-carboxy-4(1H)-quinolones. This class of inhibitors has been selected via receptor-based virtual screening of the Otava compound library. It was revealed that the most active compounds, 5,6,8-trichloro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid (7) (IC 50 = 0.3 μM) and 4-oxo-1,4-dihydrobenzo[h]quinoline-3-carboxylic acid (9) (IC50 = 1 μM), are ATP competitive (Ki values are 0.06 and 0.28 μM, respectively). Evaluation of the inhibitors on seven protein kinases shows considerable selectivity toward CK2. According to theoretical calculations and experimental data, a structural model describing the key features of 3-carboxy-4(1H)-quinolones responsible for tight binding to CK2 active site has been developed.

N-((phenyl, benzodioxinyl or N-heteroarylpiperazinyl)alkyl)-N-(N-heteroaryl)substituted carboxamides

Piperazine derivatives of formula I and their pharmaceutically acceptable acid addition salts are 5-HT1A binding agents, particularly 5-HT1A antagonists and may be used, for example, as anxiolytics. In the formula A is C2-4 alkylene chain optionally substituted by lower alkyl, Z is oxygen or sulphur, R is hydrogen or lower alkyl, R1 is a mono or bicyclic aryl or heteroaryl radical, R2 is a mono or bicyclic heteroaryl radical and R3 is hydrogen or a specified radical such as lower alkyl, cycloalkyl, aryl, heteroaryl or optionally substituted amino.

PIPERAZINE DERIVATIVES AS 5-HT ANTAGONISTS

This invention concerns compounds of formula (I) STR1 where A is a C 1 or C 2 alkylene chain optionally substituted by lower alkyl; Z is a bicyclic oxygen-containing aryl radical (e.g. 2,3-dihydro-1,4-benzodioxin-5-yl); R is hydrogen or lower alkyl; R 1 is aryl or aryl(lower)alkyl; R 2 is hydrogen or lower alkyl; and R 3 is hydrogen, an alkyl group of 1 to 10 carbon atoms, cycloalkyl of 3 to 12 carbon atoms; cycloalkyl(lower)alkyl, aryl or aryl(lower)alkyl or R. sup.2 and R 3 together with the nitrogen atom to which they are both attached represent a saturated heterocyclic ring which may contain a further hetero atom, and the pharmaceutically acceptable acid addition salts thereof. The compounds are 5-HT 1A-antagonists which may be used, for example, in treating anxiety.